Cargando…

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()

Human monoclonal antibody CH58 isolated from an RV144 vaccinee binds at Lys169 of the HIV-1 Env gp120 V2 region, a site of vaccine-induced immune pressure. CH58 neutralizes HIV-1 CRF_01 AE strain 92TH023 and mediates ADCC against CD4 + T cell targets infected with CRF_01 AE tier 2 virus. CH58 and ot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicely, Nathan I., Wiehe, Kevin, Kepler, Thomas B., Jaeger, Frederick H., Dennison, S. Moses, Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Robb, Merlin L., O'Connell, Robert J., Michael, Nelson L., Kim, Jerome H., Liao, Hua-Xin, Munir Alam, S., Hwang, Kwan-Ki, Bonsignori, Mattia, Haynes, Barton F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534707/ https://www.ncbi.nlm.nih.gov/pubmed/26288844 http://dx.doi.org/10.1016/j.ebiom.2015.06.016

Ejemplares similares

Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees
por: Choi, Ickwon, et al.
Publicado: (2015)

IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
por: Fischinger, Stephanie, et al.
Publicado: (2020)

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2015)

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens
por: Karnasuta, Chitraporn, et al.
Publicado: (2017)

V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site
por: McLellan, JS, et al.
Publicado: (2012)

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144
por: Perez, Lautaro G., et al.
Publicado: (2017)

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
por: Montefiori, David C., et al.
Publicado: (2012)

HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis
por: Wills, Saintedym, et al.
Publicado: (2018)

RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection
por: Lewitus, Eric, et al.
Publicado: (2021)

CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants
por: Dommaraju, Kalpana, et al.
Publicado: (2014)

Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
por: Edlefsen, Paul T., et al.
Publicado: (2015)

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection
por: Wang, Yufei, et al.
Publicado: (2017)

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
por: Gottardo, Raphael, et al.
Publicado: (2013)

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor
por: Peachman, Kristina K., et al.
Publicado: (2015)

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
por: Fourati, Slim, et al.
Publicado: (2019)

RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2020)

Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2021)

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial
por: Easterhoff, David, et al.
Publicado: (2017)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
por: Akapirat, Siriwat, et al.
Publicado: (2018)

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees
por: Yates, Nicole L., et al.
Publicado: (2018)

Aggregate complexes of HIV-1 induced by multimeric antibodies
por: Stieh, Daniel J, et al.
Publicado: (2014)

Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E
por: Ratto-Kim, Silvia, et al.
Publicado: (2015)

An HIV Vaccine for South-East Asia—Opportunities and Challenges
por: Pitisuttithum, Punnee, et al.
Publicado: (2013)

P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand
por: Pitisuttithum, P, et al.
Publicado: (2009)

Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability
por: Shubin, Zhanna, et al.
Publicado: (2023)

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
por: Easterhoff, David, et al.
Publicado: (2020)

Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier
por: Bonsignori, Mattia, et al.
Publicado: (2018)

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family
por: Bonsignori, M, et al.
Publicado: (2012)

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection
por: Auclair, Sarah, et al.
Publicado: (2018)

A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination
por: Lemke, Melissa M., et al.
Publicado: (2021)

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
por: Zolla-Pazner, Susan, et al.
Publicado: (2014)

Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2011)

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women
por: Gilbert, Peter B., et al.
Publicado: (2017)

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
por: Zolla-Pazner, Susan, et al.
Publicado: (2013)

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders
por: Janes, Holly, et al.
Publicado: (2015)

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcγR Complex Formation After Vaccination
por: Lemke, Melissa M., et al.
Publicado: (2022)

Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Envelope Deglycosylation Enhances Antigenicity of HIV-1 gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies
por: Ma, Ben-Jiang, et al.
Publicado: (2011)

Etiology, Clinical Course, and Outcomes of Pneumonia in the Elderly: A Retrospective and Prospective Cohort Study in Thailand
por: Osman, Mayada, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mdrjt3lm6m0jurrjnsl13eva51